2016 年第 6 期 第 14 卷

顺铂并紫杉醇化疗方案同步放化疗治疗肺癌的临床研究

作者：

单位：

关键词：顺铂紫杉醇同步放化疗肺癌

• 摘要：
• 【摘要】目的：研究顺铂并紫杉醇化疗方案同步放化疗治疗非小细胞肺癌（NSCLC）的临床疗效；方法：选择2013年8月——2014年7月于我院肿瘤科接受治疗的中晚期NSCLC患者118例，依照随机数字表法1:1分为实验组（n=59）与对照组（n=59），两组基线资料无统计学差异（p＜0.05）。对照组患者给予放射治疗，实验组联合放射治疗与顺铂并紫杉醇化疗。观察两组治疗前后CRP（C反应蛋白）、TNF-α（肿瘤坏死因子-α）、IL-6（白细胞介素-6）等炎性因子水平；观察治疗前后PDCD5(程序化细胞死亡分子5)蛋白水平；毒副作用；结果：实验组6个月DCR率（77.97%）显著高于对照组（61.02%），有统计学差异（p＜0.05）。实验组平均生存时间（16.87±3.85）个月显著高于对照组（13.56±2.73）个月，有统计学差异（p＜0.05）；实验组1年生存率（81.36%）高于对照组（61.02%），有统计学差异（p＜0.05）。实验组治疗后CRP、TNF-α、IL-6水平均低于对照组，PDCD5蛋白水平高于对照组，组间有统计学差异（p＜0.05）。实验组骨髓抑制、及III、IV级粒细胞减少发生率高于对照，组间有统计学差异（p＜0.05）；结论：顺铂并紫杉醇同步放化疗治疗NSCLC疗效优于单纯放疗，可显著改善患者体内炎性因子及PDCD5水平，但其毒副作用较单纯放疗严重。
• Objective To study the clinical effect of concurrent chemoradiation therapy with paclitaxel and cisplatin for lung cancer. Methods Selected 118 cases of medium and advanced NSCLC who were in our hospital from August 2013 to July 2014, and they were divided into experiment group(n=59) and control group(n=59) randomly. The general data of two groups had no statistically difference(P<0.05)。The control group were taken radiotherapy, while the experiment group were taken concurrent chemoradiation therapy. Then, Measuring the level of CRP, TNF-α and IL-6 pretherapy and post-treatment, Observing the express of PDCD5 protein, toxic and side effect. Results DCR rate of experiment group(77.97%) is significantly higher than control group(61.02%), it’s statistically significant(P<0.05). the average survival time(16.87±3.85 months) is more longer than control group(13.56±2.73 months), with statistically significant(P<0.05). one-year survival rate of experiment group(81.36%) is significantly longer than the control one(61.02) and it has significantly statistically(p<0.05). CRP, TNF-α and IL-6 is lower than control group, however the PDCD5 protein content is higher than control group, the difference is statistically significant(P<0.05). The bone marrow suppression, and grade III or IV granulocytopenia incidence of Experimental group is higher than the control, the difference between groups is statistically (p<0.05). Conclusion The clinical effect of concurrent chemoradiation therapy with paclitaxel and cisplatin for lung cancer is superior to Radiotherapy alone, it can Significantly improve the patient's body inflammatory factor and level of PDCD5, but the side effects is serious than radiotherapy alone.